MA33566B1 - Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux - Google Patents

Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux

Info

Publication number
MA33566B1
MA33566B1 MA34666A MA34666A MA33566B1 MA 33566 B1 MA33566 B1 MA 33566B1 MA 34666 A MA34666 A MA 34666A MA 34666 A MA34666 A MA 34666A MA 33566 B1 MA33566 B1 MA 33566B1
Authority
MA
Morocco
Prior art keywords
thihydtoin
etrorylamtia
anticancer drugs
alternative used
prophylaxis
Prior art date
Application number
MA34666A
Other languages
Arabic (ar)
English (en)
Inventor
Ulrich Lücking
Arwed Cleve
Bernard Haendler
Gimenez Hortensia Faus
Silk Köhr
Horst Irlbacher
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33566B1 publication Critical patent/MA33566B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

CETTE INVENTION CONCERNE DES THIOHYDANTOÏNES (HÉTÉROARYLMÉTHYL) SUBSTITUÉES DE FORMULE GÉNÉRALE (I) ET LEURS PROCÉDÉS DE PRÉPARATION, LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PROPHYLAXIE DE CERTAINES AFFECTIONS, ET LEUR UTILISATION DANS LA PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE DE CERTAINES AFFECTIONS, EN PARTICULIER LE CANCER DE LA PROSTATE.
MA34666A 2009-09-11 2012-03-08 Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux MA33566B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (fr) 2009-09-11 2010-08-28 Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux

Publications (1)

Publication Number Publication Date
MA33566B1 true MA33566B1 (fr) 2012-09-01

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34666A MA33566B1 (fr) 2009-09-11 2012-03-08 Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux

Country Status (28)

Country Link
US (1) US20120251551A1 (fr)
EP (1) EP2475653A1 (fr)
JP (1) JP2013504523A (fr)
KR (1) KR20120065396A (fr)
CN (1) CN102639523A (fr)
AR (1) AR078166A1 (fr)
AU (1) AU2010294588A1 (fr)
BR (1) BR112012005526A2 (fr)
CA (1) CA2773591A1 (fr)
CL (1) CL2012000623A1 (fr)
CO (1) CO6511228A2 (fr)
CR (1) CR20120113A (fr)
CU (1) CU20120042A7 (fr)
DO (1) DOP2012000063A (fr)
EA (1) EA201200473A1 (fr)
EC (1) ECSP12011716A (fr)
IL (1) IL218390A0 (fr)
IN (1) IN2012DN02081A (fr)
MA (1) MA33566B1 (fr)
MX (1) MX2012002977A (fr)
NZ (1) NZ598643A (fr)
PE (1) PE20121180A1 (fr)
PH (1) PH12012500497A1 (fr)
SG (1) SG178919A1 (fr)
TN (1) TN2012000108A1 (fr)
TW (1) TW201111378A (fr)
UY (1) UY32882A (fr)
WO (1) WO2011029537A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533797B1 (fr) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Composé hétérocyclique
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014153280A1 (fr) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
CA3161836A1 (fr) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibiteur de la demethylase-1 specifique de la lysine
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601253B1 (fr) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
CA3057891A1 (fr) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Nouveaux composes macrocycliques inhibiteurs de ptefb
EP3625215B1 (fr) 2017-05-18 2023-09-13 PI Industries Ltd Composés de formimidamidine utile contre les microorganismes phytopathogeniques
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
EP3953342B1 (fr) 2019-04-11 2025-09-24 University of Miami Inhibiteurs améliorés du complexe d'activation transcriptionnelle notch et leurs méthodes d'utilisation
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (fr) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 Procédé de synthèse d'un dérivé de thiohydantoïne au moyen d'un procédé en une étape
CN122249431A (zh) * 2023-11-17 2026-06-19 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO2000017163A1 (fr) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de cyanophenyle
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
CA2529292A1 (fr) 2003-07-02 2005-01-20 Merck & Co., Inc. Antibiotiques a base d'oxazolidinone et derives
AR045955A1 (es) 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
EP2228369A1 (fr) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Derives de pyrazole comme modulateurs de proteine kinase
WO2006013887A1 (fr) 2004-08-03 2006-02-09 Chugai Seiyaku Kabushiki Kaisha Nouveaux dérivés imidazolidine
KR20070106969A (ko) * 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
MX2007006387A (es) 2004-12-03 2007-06-20 Hoffmann La Roche Derivados de piridina 3-substituidos como antagonistas h3.
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
WO2009097995A1 (fr) * 2008-02-07 2009-08-13 Sanofi-Aventis Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation

Also Published As

Publication number Publication date
CN102639523A (zh) 2012-08-15
UY32882A (es) 2011-04-29
AU2010294588A1 (en) 2012-04-05
CA2773591A1 (fr) 2011-03-17
CL2012000623A1 (es) 2012-09-14
NZ598643A (en) 2013-10-25
IN2012DN02081A (fr) 2015-08-21
MX2012002977A (es) 2012-04-30
TW201111378A (en) 2011-04-01
SG178919A1 (en) 2012-04-27
DOP2012000063A (es) 2012-05-15
IL218390A0 (en) 2012-04-30
KR20120065396A (ko) 2012-06-20
WO2011029537A1 (fr) 2011-03-17
ECSP12011716A (es) 2012-04-30
US20120251551A1 (en) 2012-10-04
AR078166A1 (es) 2011-10-19
TN2012000108A1 (en) 2013-09-19
JP2013504523A (ja) 2013-02-07
CO6511228A2 (es) 2012-08-31
PH12012500497A1 (en) 2012-10-22
CR20120113A (es) 2012-05-02
EP2475653A1 (fr) 2012-07-18
CU20120042A7 (es) 2012-06-21
BR112012005526A2 (pt) 2016-04-26
PE20121180A1 (es) 2012-08-24
EA201200473A1 (ru) 2012-10-30

Similar Documents

Publication Publication Date Title
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
CA2871471C (fr) Inhibiteurs d'adn pk
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MX350010B (es) Inhibidores syk de imidazopiridinas.
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
EP4400172A3 (fr) Dérivés de pipéridin-4-ylazétidine en tant qu'inhibiteurs de jak1
WO2013112950A3 (fr) Entités chimiques particulières, compositions et procédés
WO2011017534A3 (fr) Traitement du cancer de la prostate
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA39145B1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA34845B1 (fr) Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication
MA38925A1 (fr) Dérivés de phénylalanine substitués
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
Jiang et al. Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/apyrimidinic endonuclease 1
EA201390598A1 (ru) Антагонист мутантного андрогенного рецептора
EA201170885A1 (ru) Новые производные ретиноидов, обладающие цитотоксическими и/или антиангиогенными свойствами
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
FR2985256B1 (fr) Derives piperazinyles pour le traitement de cancers